ApToll
Jump to navigation
Jump to search
Indications
- ischemic stroke in combination with endovascular thrombectomy
Mechanism of action
- a DNA oligonucleotide that is an antagonist at toll-like receptor 4, a receptor directly involved in innate immune responses
References
- ↑ Hernandez-Jimenez M, Abad-Santos F, Cotgreave I et al Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment. A Phase 1/2 Randomized Clinical Trial. JAMA Neurol. Published online June 20, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37338893 PMCID: PMC10282959 Free PMC article https://jamanetwork.com/journals/jamaneurology/fullarticle/2806243